Odds of response based on generalised estimating equation for treatment response at ≤300 copies/ml
| Variables | Odds | SE | z | P>|z| | (95% CI) |
|---|---|---|---|---|---|
| Main effects | |||||
| Main effects | 0.847 | 0.017 | −8.160 | 0.000 | 0.814 to 0.882 |
| LPCR_0 (centred) | 4.175 | 0.893 | 6.680 | 0.000 | 2.745 to 6.349 |
| Treatment, ETV | 0.243 | 0.139 | −2.470 | 0.013 | 0.079 to 0.746 |
| HBeAg (positive) | 1.026 | 0.005 | 5.290 | 0.000 | 1.016 to 1.035 |
| Time (centred at 48 weeks) | 0.637 | 0.359 | −0.800 | 0.424 | 0.212 to 1.921 |
| Clinical study (ID=27)/Interaction terms | 1.035 | 0.008 | 4.710 | 0.000 | 1.020 to 1.050 |
| ETV * Time (centered at 48 wks) | 0.952 | 0.028 | −1.660 | 0.096 | 0.899 to 1.009 |
| ETV *PCR (centered at 48 wks) | 1.303 | 1.303 | 1.080 | 0.278 | 0.808 to 2.101 |
ETV, entecavir; LPCR_0, natural log of baseline HBV DNA measured by PCR assay.